score of like 26, 27 where we really don’t have good information about whether we should be using chemotherapy, and estimators for benefit from chemotherapy. I too have logged in and started using it a little bit in my patients to show them this pseudo individualized treatment response ...
Early-stage breast cancer treatment: given the complex nature of the disease, the ability to clearly explain the therapeutic options available to patients with breast cancer is invaluable.Kentley, Donna
Clinical trials help researchers find new, better treatments. But not all women are represented in breast cancer trials. Find out the value of diversity. Load More Lesson 7 of 7: Follow-up Care for Early-Stage Breast CancerStart Lesson Facing Early Breast Cancer With a PlanView All LessonsSee...
For patients with early-stage breast cancer who are considered high-risk for distant disease recurrence and risk of death, the use of pCR an measure of clinical efficacy may predict clinical benefit within several months of treatment, addressing unmet treatment needs in a shorter timeframe compared...
Treatment of Early-Stage Breast Cancer.Focuses on the issues concerning the treatment of first-stage breast cancer that were discussed during a convention held by the National Cancer Institute and the U.S. National Institute of Health Office of Medical Applications of Research on June 18-21, ...
“We await their results, as they will frame the future treatment algorithm for patients with early-stage triple-negative breast cancer,” Dr. Sharma commented. Predicting Benefit to Avoid Unnecessary Toxicity “The addition of immunotherapy to chemotherapy definitely improves outcomes for patients with...
The treatment of early stage breast cancer in elderly women now has two major end points: to improve disease-free survival and quality of life. Furthermore, the advent of new hormonal compounds, such as aromatase inhibitors and chemotherapeutic drugs (capecitabine and liposomal doxorubicin), less ...
informs important treatment decisions by taking into consideration both efficacy and potential side effects that are associated with some therapies, such as those used in premenopausal patients with early-stage breast cancer. Dr Graff advises clinicians to leave second options for treatment on the table...
Table 3 provides the factors associated with Over St Gallen treatment. Women with breast cancer in stage II had more than four times the probability of being treated Over St Gallen (RRR = 4.15, 95% CI 2.90–5.94) compared to women with breast cancer in stage I. Cancers positive to ...
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response. ...